- •Dedication
- •Preface
- •Acknowledgements
- •Contributors
- •Contents
- •1. Minimally Invasive Oculoplastic Surgery
- •1.1 General Points
- •1.2 Lower Lid Entropion
- •1.2.1 Introduction
- •1.2.2 Lower Lid Entropion Sutures
- •1.2.3 Lower Lid Entropion Botulinum Toxin
- •1.3 Lower Lid Ectropion
- •1.3.1 Introduction
- •1.3.2 The Royce Johnson Suture
- •1.3.3 The Pillar Tarsorrhaphy
- •1.4 Distichiasis
- •1.4.1 Introduction
- •1.4.2 Direct Excision of Lashes
- •1.5 Ptosis
- •1.5.1 Introduction
- •1.5.3 Anterior Approach – One Stitch Aponeurosis Repair
- •1.5.4 Supramid Brow Suspension
- •1.6 Lid Retraction
- •1.6.1 Introduction
- •1.6.2 Koornneef Blepharotomy
- •1.6.3 Botulinum Toxin
- •1.7 Lid Tumours
- •1.7.1 Mohs’ Micrographic Surgery
- •1.7.2 Lamella Sparing Tumour Excision
- •References
- •2. Minimally Invasive Conjunctival Surgery
- •2.1 Conjunctival Surgery
- •2.2 Conjunctivochalasis
- •2.2.1 Background of the Disease
- •2.2.2 Indication for Surgery
- •2.2.3 Basic Concept of Surgery
- •2.2.4 Surgical Procedure
- •2.2.5 Postoperative Follow-Up
- •2.3 Pterygium
- •2.3.1 Background of the Disease and the Concept of Minimally Invasive Surgery
- •2.3.2 Indication for Surgery
- •2.3.3 Basic Concept of Surgery
- •2.3.4 Surgical Procedures
- •2.3.5 A Biologic Adhesive for Sutureless Pterygium Surgery
- •2.3.6 Postoperative Follow-Up
- •2.4 Limbal and Conjuntival Dermoids
- •2.4.1 Background of the Disease
- •2.4.2 Basic Concept of Surgery
- •2.4.3 Surgical Procedure
- •2.4.4 Postoperative Follow-Up
- •2.5 Strabismus Surgery
- •2.6 Conclusion
- •References
- •3. Minimally Invasive Lacrimal Surgery
- •3.1 Introduction
- •3.1.1 Causes of Stenoses of the Lacrimal Drainage System
- •3.1.3 General Remarks Regarding Surgical Management
- •3.2 Endonasal Endoscopic (Microscopic) Dacryocystorhinostomy (EDCR)
- •3.2.1 Indication for EDCR
- •3.2.2 Surgical Technique
- •3.2.3 Silicone Stenting for EDCR
- •3.2.2.1 Silicone “Cones” (Lacrimal Duct Stent, Bess, Berlin)
- •3.2.4 Use of Mitomycin C for EDCR
- •3.2.5 Post-Operative Care After EDCR
- •3.2.6 Results of EDCR
- •3.3 Endonasal Endoscopic Laser Dacryocystorhinostomy (ELDCR)
- •3.3.1 Indications for ELDCR
- •3.3.2 Contraindications for ELDCR
- •3.3.3 Surgical Technique for ELDCR
- •3.3.4 Potential Problems with ELDCR
- •3.3.5 Post-Operative Care After ELDCR
- •3.3.6 Results of ELDCR
- •3.4 Dacryoendoscopy with Transcanalicular Laserdacryoplasty (TLDP)
- •3.4.1 Indication for TLDP
- •3.4.2 Contraindication for TLDP
- •3.4.3 Surgical Technique for TLDP
- •3.4.4 Results of TLDP
- •3.5 Microdrill Dacryoplasty (MDP)
- •3.5.1 Indication for MDP
- •3.5.2 Contraindication for MDP
- •3.5.3 MDP Procedure
- •3.5.4 Results of MDP
- •3.6 Balloon Dilatation
- •3.6.1 Indications for Balloon Dilatation
- •3.6.2 Anaesthesia for Balloon Dilatation
- •3.6.3 Surgical Technique with 2 mm or 3 mm Balloon for Incomplete Stenosis
- •3.6.3.1 Post-Operative Care
- •3.6.3.2 Complications
- •3.6.3.3 Results
- •3.6.4.1 Post-Operative Care
- •3.6.4.2 Results
- •3.6.4.3 Complications
- •3.7 Stent Placement
- •3.7.1 Indications for Stent Placement
- •3.7.3 Surgical Technique for Stent Placement
- •3.7.5 Results of Stent Placement
- •References
- •4. Minimally Invasive Corneal Surgery
- •4.1 Penetrating Keratoplasty
- •4.1.1 Introduction
- •4.1.2 Indications
- •4.1.3 Preoperative Evaluation of the Keratoplasty Patient
- •4.1.4 Preparation for Penetrating Keratoplasty
- •4.1.4.1 Eyelid Speculum
- •4.1.4.2 Scleral Fixation Rings
- •4.1.4.3 Large and Fine-Tipped Needle Holder
- •4.1.4.4 Toothed Forceps
- •4.1.4.5 Trephine Blades
- •4.1.4.6 Radial Marker
- •4.1.4.7 Cornea Punch
- •4.1.4.8 Cutting Block
- •4.1.4.9 Scissors
- •4.1.4.10 Cannulas and Blades
- •4.1.5 Preoperative Medications
- •4.1.6 Penetrating Keratoplasty Surgical Procedure
- •4.1.6.1 Placement of the Scleral Fixation Ring
- •4.1.6.2 Marking of the Host Cornea
- •4.1.6.3 Sizing of the Trephine
- •4.1.6.4 Trephination of the Host Cornea
- •4.1.6.5 Trephination of the Donor Cornea
- •4.1.6.6 Removal of the Host Cornea
- •4.1.6.7 Placement of the Donor Cornea Tissue in the Host Stromal Bed
- •4.1.6.8 Placement of the Cardinal Sutures
- •4.1.6.9 Completion of Suturing
- •4.1.6.10 Suture Techniques
- •4.1.6.11 Subconjunctival Medications
- •4.1.7 Intraoperative Complications
- •4.1.7.1 Scleral Perforation
- •4.1.7.2 Damage to the Donor Button
- •4.1.7.4 Posterior Capsule Rupture
- •4.1.7.5 Vitreous Loss
- •4.1.7.6 Anterior Chamber Hemorrhage
- •4.1.7.7 Choroidal Hemorrhage
- •4.1.8 Postoperative Management
- •4.1.8.1 Postoperative Immunosuppressive Regimen
- •4.1.9 Postoperative Complications
- •4.1.9.1 Wound Leaks
- •4.1.9.2 Epithelial Defects
- •4.1.9.3 Suture-Related Problems
- •4.1.9.4 Increased Intraocular Pressure
- •4.1.9.5 Post-Keratoplasty Astigmatism
- •4.1.10.1 Wedge Resections and Compression Sutures
- •4.1.10.2 Relaxing Incisions
- •4.1.10.3 LASIK
- •4.1.10.4 Photorefractive Keratectomy with Mitomycin C
- •4.1.11 Corneal Allograft Rejection
- •4.1.11.1 Host Risk Factors
- •4.1.11.2 Vascularized Corneas
- •4.1.11.3 Prior Graft Loss
- •4.1.11.4 Graft Diameter
- •4.1.11.5 Anterior Synechiae
- •4.1.11.6 Previous Intraocular Surgery
- •4.1.11.7 Herpes Simplex
- •4.1.12 Treatment of Allograft Rejection
- •4.1.13 Large Diameter Penetrating Keratoplasty
- •4.1.14 Summary
- •References
- •4.2 Descemet’s Stripping Endothelial Keratoplasty
- •4.2.1 Introduction
- •4.2.2 Descemet’s Stripping Endothelial Keratoplasty Surgical Technique
- •4.2.2.1 Donor Cornea Preparation
- •4.2.2.2 Host Cornea Preparation
- •4.2.2.3 Insertion of the Donor Cornea
- •4.2.3 Postoperative Medications
- •4.2.4 Donor Dislocation Risks
- •4.2.5 Repositioning Donor Tissue
- •4.2.6 Treatment of Rejection Episodes
- •4.2.7 Visual and Refractive Outcomes
- •4.2.8 Other Complications
- •4.2.9 Summary
- •References
- •4.3 Pterygium
- •4.3.1 Introduction
- •4.3.2 Treatment of Pterygium
- •4.3.3 Surgical Technique
- •4.3.3.1 Removal of the Pterygium
- •4.3.3.2 Harvesting the Conjunctival Autograft
- •4.3.3.3 Securing the Conjunctival Autograft
- •4.3.3.4 Fibrin Glue vs. Nylon Sutures
- •4.3.4 Postoperative Management
- •4.3.5 Recurrent Pterygium
- •4.3.6 Other Techniques in Pterygium Removal
- •4.3.6.1 Bare Scleral Technique
- •4.3.6.2 Adjunctive Agents
- •Mitomycin C
- •Beta-Irradiation
- •4.3.6.3 Amniotic Membrane Transplantation
- •4.3.7 Complications in Pterygium Removal
- •4.3.8 Summary
- •References
- •5. Minimally Invasive Refractive Surgery
- •5.1 Trends in Refractive Surgery
- •5.2 Introduction
- •5.3 Cornea Refractive Surgery
- •5.3.1 Laser In Situ Keratomileusis (LASIK)
- •5.3.1.1 Advances in Flap Creation Technology
- •Microkeratomes
- •Femtosecond Laser
- •5.3.1.2 Technological Advances in Laser Delivery Platforms
- •5.3.1.3 Faster Excimer Lasers
- •5.3.1.4 Reduction of Collateral Thermal Tissue Damage
- •5.3.1.5 Advanced Eye Trackers
- •5.3.2 PRK and Advanced Surface Ablations (ASA)
- •5.3.2.1 Decrease Thermal Load on the Cornea
- •5.3.2.2 Use of Wound-Healing Modulators
- •5.3.2.3 Trend Towards EPI-LASIK
- •5.3.3 Summary
- •5.4 Intraocular Refractive Surgery
- •5.4.1 Phakic Intraocular Lens Surgery
- •5.4.1.1 Advances in Diagnostic Equipment
- •5.4.1.2 Types of Phakic Intraocular Lens
- •5.4.1.3 Kelman-Duet Phakic Intraocular Lens
- •Lens Design
- •Surgical Technique
- •Pre-Operative Preparation
- •Operative Procedure
- •Post-Operative Care
- •Results
- •Refractive Outcomes
- •Corneal Endothelium
- •5.4.1.4 Visian Implantable Collamer Lens
- •Lens Design
- •Surgical Technique
- •Pre-Operative Preparation
- •Operative Procedure
- •Post-Operative Care
- •5.4.1.5 Results
- •5.4.2 Summary
- •5.5 Lens and Cataract Surgery
- •5.5.2 The Ideal MICS Intraocular Lens
- •5.5.2.1 Aspheric Intraocular Lenses
- •5.5.2.2 Toric Intraocular Lenses
- •5.5.2.3 ACRI.LISA 366D and ACRI.LISA TORIC 466TD
- •Lens Design
- •5.5.2.4 Surgical Technique
- •Operative Procedure
- •Post-Operative Care
- •5.5.2.5 Results
- •5.5.3 Summary
- •5.6 The Future: Beyond the Horizon of Refractive Surgery Today
- •Reference
- •6. Minimally Invasive Strabismus Surgery
- •6.1 Introduction
- •6.2 Nonsurgical Treatment
- •6.4 Rectus Muscle Procedures
- •6.4.1 MISS Rectus Muscle Recession
- •6.4.2 MISS Rectus Muscle Plication
- •6.4.3 Parks’ Rectus Muscle Recession
- •6.4.4 Parks’ Rectus Muscle Plication
- •6.4.5 MISS Rectus Muscle Posterior Fixation Suture
- •6.4.7 MISS Rectus Muscle Repeat Surgery
- •6.4.8 MISS Rectus Muscle Transposition Surgery
- •6.5 Oblique Muscle Procedures
- •6.5.1 MISS Inferior Oblique Muscle Recession
- •6.5.2 MISS Inferior Oblique Muscle Plication
- •6.5.3 MISS Superior Oblique Muscle Recession
- •6.5.4 MISS Superior Oblique Muscle Plication
- •6.5.6 Mühlendyck’s Partial Posterior Superior Oblique Tenectomy for Congenital Brown’s Syndrome
- •6.6 Postoperative Handling
- •6.7.1 Intraoperative Complications
- •6.7.2 Postoperative Complications
- •6.8 Suggestions on How to Start Doing MISS
- •6.8.1 Instruments Suitable for MISS
- •6.8.2 Suture Materials Used for MISS
- •6.8.3 General Remarks Regarding MISS Procedures
- •6.8.4 MISS Dose–Response Relationships
- •References
- •7. Minimally Invasive Iris Surgery
- •7.1 Instrumentation
- •7.2 Sutures
- •7.3 Surgical Principles of Iris Suturing
- •7.3.1 Mobilization
- •7.3.2 Intraocular Suturing and Knot Tying
- •7.3.3 Reattachment of Iris to Sclera
- •7.3.4 Pupil Repair
- •7.3.5 Adjunctive Pupil Repair Techniques
- •References
- •8. Minimally Invasive Glaucoma Surgery
- •Introduction
- •8.1.1 Introduction to Deep Sclerectomy
- •8.1.2 Anesthesia
- •8.1.3 Surgical Technique
- •8.1.3.1 Preparation
- •8.1.3.3 Deep Flap Preparation
- •8.1.3.5 Peeling of Schlemm’s Canal and Juxtacanalicular Meshwork
- •8.1.3.6 Drainage Device
- •8.1.3.7 Wound Closure
- •8.1.4 Postoperative Management and Medication
- •8.1.4.1 Medication
- •8.1.4.2 Management
- •8.1.5 Adjunctive Treatments
- •8.1.5.1 Bleb Needling
- •8.1.5.2 Nd:YAG Goniopuncture
- •8.1.6 Complications and Management
- •8.1.6.1 General
- •8.1.6.2 Perioperative Complications
- •8.1.6.3 Early Postoperative Complications
- •8.1.6.4 Late Postoperative Complications
- •Open-Angle Glaucoma
- •Pigmentary Glaucoma
- •Pseudoexfoliation Glaucoma
- •Aphakic Glaucoma
- •Sturge–Weber Syndrome
- •Glaucoma Secondary to Uveitis
- •Congenital and Juvenile Glaucoma
- •Narrow-Angle Glaucoma
- •Posttrauma Angle-Recession Glaucoma
- •Neovascular Glaucoma
- •Narrow-Angle Glaucoma in a Young Patient
- •Pseudophakic Glaucoma with an A/C IOL
- •8.2.1.4 Preoperative Considerations
- •8.2.2 Anesthesia
- •8.2.4 Postoperative Management and Medication
- •8.2.5 Outcomes and Comparison with Other Techniques
- •8.2.6 Complications and Management
- •8.2.6.1 General
- •8.2.6.4 Summary and Key Points
- •References
- •8.3 New Minimally Invasive, Sclerothalamotomy Ab Interno Surgical Technique
- •8.3.1 Introduction to the Sclerothalamotomy Ab Interno
- •8.3.1.1 Indications for the Sclerothalamotomy Ab Interno
- •8.3.2 Anesthesia
- •8.3.3 Surgical Technique
- •8.3.3.1 Preparation
- •8.3.3.2 Diathermy Probe Insertion
- •8.3.4 Postoperative Management and Medication
- •8.3.5 Outcomes and Comparison with Other Techniques
- •8.3.6 Complications and Management
- •8.3.6.1 General
- •8.3.6.3 Conclusions
- •References
- •Type of Glaucoma
- •Stage of Glaucoma
- •Combined Surgery
- •8.4.2 Anesthesia
- •8.4.3 Surgical Technique
- •8.4.3.1 Preparation
- •8.4.3.2 Implantation of the Micro-Bypass Stent
- •8.4.4 Postoperative Management and Medication
- •8.4.5 Outcomes and Combination with Other Techniques
- •8.4.5.1 Trabecular Implant in Refractory Glaucoma Patients
- •8.4.6 Conclusions
- •References
- •9. Minimally Invasive Cataract Surgery
- •10. Minimally Invasive Vitreoretinal Surgery
- •10.1 Introduction
- •10.2 Microincision Vitrectomy
- •10.2.1 Models of Wound Architecture
- •10.2.2 Vitrectomy
- •10.2.3 Adjuncts
- •10.2.4 Common Surgical Techniques
- •10.2.4.1 Macular Surgery
- •10.2.4.2 Proliferative Diabetic Retinopathy
- •10.2.4.3 Retinal Detachment
- •10.2.4.4 Pediatric Vitreoretinal Surgery
- •10.2.5 Complications
- •10.2.6 Future Developments in Minimally Invasive Vitrectomy
- •10.3 Endoscopic Vitreoretinal Surgery
- •10.3.1 Introduction
- •10.3.2 History and Development of Endoscopic Ophthalmic Surgery
- •10.3.3 The Endoscope
- •10.3.4 Applications of Intraocular Endoscopy
- •10.3.4.1 Media Opacity
- •10.3.4.3 PVR and Subretinal Surgery
- •10.3.4.4 Retained Lens Fragments
- •10.3.4.5 Anterior and Retrolental Vitrectomy in Malignant Glaucoma
- •10.3.4.5 Sutured IOL and ECP
- •10.3.5 Limitations and Challenges
- •10.4 Future Directions of Minimally Invasive Vitreoretinal Surgery
- •References
- •INDEX
186 |
E. Dahan et al. |
Fig. 8.44 Healon GV¨ was evacuated from the anterior chamber with bimanual irrigation/aspiration
72 months was 14.7 ± 1.8 mmHg (range 10Ð21 mmHg) for primary open-angle glaucoma and 13.2 ± 1.3 mmHg (range 12Ð15 mmHg) for juvenile glaucoma (Figs. 8.45 and 8.46). After 72 months 77% of treated patients in the open-angle glaucoma group achieved >30% reductions of the IOP, whereas 100% of treated patients with juvenile glaucoma achieved >30% reductions of the IOP. The complete success rate, deÞned as an IOP lower than 21 mmHg without medication, was 79.2% in the group of open-angle glaucoma group and 80% in the juvenile glaucoma group at 72 months.
The average preoperative administration of pressurereducing eye agents was 2.6 (±1.0) for the open-angle
glaucoma group and 3.0 (±1.2) for the juvenile glaucoma group. After surgery, this value decreased to 0.51 (±0.97) for open-angle glaucoma group (Fig. 8.47) and 0.2 (±0.44) for the juvenile glaucoma group at 72 months.
8.3.6 Complications and Management
8.3.6.1 General
This surgery is quite a safe and efÞcient technique with few postoperative complications. As for any Þltering procedure some complications can occur and these can be rapidly identiÞed and handled to reduce the extent of such mishaps. For instance, immediate postoperative hypotony, shallow A/C, hyphema, and choroidal detachment may be present, although to a lesser degree due to the intrinsic properties of the small drainage oriÞce made by the diathermy probe. The usual directives on how to avoid these complications in other Þltrations procedures are also applicable to the sclerothalamotomy ab interno.
8.3.6.2 Specific to the Technique
Temporary IOP elevation higher than 21mmHg can be observed. In the above-mentioned trial about 22.6% of all cases encountered such a complication. These patients a responded well to pressure-reducing treatment with one agent and medication could gradually be withdrawn
Fig. 8.45 Average level of intraocular pressure after sclerothalamotomy ab interno surgery for all 53 cases with open-angle glaucoma
50
45
40
35
30
25 
20
15
10
5
0
preop |
|
|
|
|
|
monthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonth |
||||||||||||||||||||||||
|
1d |
2d |
3d |
4d |
7d |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
3 |
6 |
9 |
12 |
15 |
18 |
21 |
24 |
27 |
30 |
33 |
36 |
39 |
42 |
45 |
48 |
51 |
54 |
57 |
60 |
63 |
66 |
69 |
72 |
8 Minimally Invasive Glaucoma Surgery |
187 |
Fig. 8.46 Average level of intraocular pressure after sclerothalamotomy ab interno surgery for all Þve cases with juvenile glaucoma
mmHg
50
45
40
35
30
25
20
15
10
5
0
preop |
|
|
|
|
|
monthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonthmonth |
||||||||||||||||||||||||
|
1d |
2d |
3d |
4d |
7d |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
3 |
6 |
9 |
12 |
15 |
18 |
21 |
24 |
27 |
30 |
33 |
36 |
39 |
42 |
45 |
48 |
51 |
54 |
57 |
60 |
63 |
66 |
69 |
72 |
time in months
Fig. 8.47 Administration of pressure-reducing eye agents during 72 months for the open-angle glaucoma group
|
2.8 |
|
|
|
|
|
|
|
|
|
|
2.7 |
|
|
|
|
|
|
|
|
|
|
2.6 |
|
|
|
|
|
|
|
|
|
|
2.5 |
|
|
|
|
|
|
|
|
|
|
2.4 |
|
|
|
|
|
|
|
|
|
|
2.3 |
|
|
|
|
|
|
|
|
|
|
2.2 |
|
|
|
|
|
|
|
|
|
|
2.1 |
|
|
|
|
|
|
|
|
|
eye |
2 |
|
|
|
|
|
|
|
|
|
1.9 |
|
|
|
|
|
|
|
|
|
|
1.8 |
|
|
|
|
|
|
|
|
|
|
reducing |
|
|
|
|
|
|
|
|
|
|
1.7 |
|
|
|
|
|
|
|
|
|
|
1.6 |
|
|
|
|
|
|
|
|
|
|
1.5 |
|
|
|
|
|
|
|
|
|
|
1.4 |
|
|
|
|
|
|
|
|
|
|
1.3 |
|
|
|
|
|
|
|
|
|
|
- |
1.2 |
|
|
|
|
|
|
|
|
|
pressure |
|
|
|
|
|
|
|
|
|
|
1.1 |
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
0.9 |
|
|
|
|
|
|
|
|
|
|
0.8 |
|
|
|
|
|
|
|
|
|
|
|
0.7 |
|
|
|
|
|
|
|
|
|
|
0.6 |
|
|
|
|
|
|
|
|
|
|
0.5 |
|
|
|
|
|
|
|
|
|
|
0.4 |
|
|
|
|
|
|
|
|
|
|
0.3 |
|
|
|
|
|
|
|
|
|
|
0.2 |
|
|
|
|
|
|
|
|
|
|
0.1 |
|
|
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
preop |
1 month |
3 |
6 |
12 |
24 |
36 |
48 |
60 |
72 |
|
|
|
months |
months |
months |
months |
months |
months |
months |
months |
time in months
in all of these patients. Conversely, hypotension may be present that can last for a few days after surgery.
The trabecular meshwork and SchlemmÕs canal are removed with the high-frequency diathermy probe. Despite the automatic cautery provided by the diathermy probe, it is possible that some small vessels from the iris vascular circle may be affected. Some hemorrhage will result from such insult. Mild hyphema can be observed for a few days after surgery which disappears within the Þrst 2 weeks after the procedure. Similarly the spooling of blood in the anterior chamber
can trigger transient Þbrin formation (Fig. 8.48). Fibrin can be cleared within 1 day after frequent application of topical corticosteroids.
Transient IOP elevation after sclerothalamotomy ab interno may occur in the Þrst 6 weeks and can be effectively brought under control with the use of a topical antiglaucoma medication. In most of the cases, this therapy can be gradually withdrawn after 3 weeks postsurgery. It is believed that moderate tissue swelling around the thalami could be the reason for transient postoperative IOP peaks.
188 |
|
|
|
|
E. Dahan et al. |
Fig. 8.48 Complications |
1.9% |
|
|
|
Temporary IOP |
after sclerothalamotomy ab |
|
|
|
|
elevation |
interno surgery for the |
11.4% |
|
|
|
Temporary |
open-angle glaucoma group |
|
|
|
||
|
|
|
|||
|
|
|
|
|
hypotension |
|
|
22.6% |
|
|
Hyphema |
|
|
|
|||
|
|
|
|
|
|
|
1.9% |
|
|
|
Temporary fibrin |
|
|
|
|
||
|
|
|
|
|
formation |
To be efÞcient the high-frequency diathermy creates a thermal energy in the tissues surrounding the probe whereas the temperature at the tip can easily reach 130¡C. While the temperature is focused on a small area, we cannot rule out that some of this thermal energy may spread to the surrounding tissues. We cannot rule out that some of this thermal energy may affect the metabolism of the lens. Some degree of cataract development after sclerothalamotomy ab interno have been reported and some cases have resulted in a decrease in the visual acuity.
8.3.6.3 Conclusions
Sclerothalamotomy ab interno is a new surgical technique for treating open-angle glaucoma and juvenile glaucoma. This ab interno method creats a direct channel between the anterior chamber and the outer portion of SchlemmÕs canal. Persistence of the sclerotomy can be investigated with a three-mirror goniolens. Sclerothalamotomy ab interno creates a deep sclerotomy with subsequent access of aqueous to the scleral layer. Both aspects may facilitate a bypass effect of aqueous outßow. In light of the fact that about 85% of the aqueous humor drains through the trabecular meshwork, we suspect there is an additional route for aqueous humor absorption in the case of elevated IOP. There is evidence in the literature that such bypass effects which do not lead to the formation of Þltering blebs may be present after surgical intervention. In a previous study [11], it was ascertained that eyes without Þlter bleb exhibited very stable long-term IOP regulation postoperatively. In addition to the bypassing of trabecular outßow resistance caused by sclerothalamotomy ab interno treatment, outßow resistance may be further reduced by scleral thinning at the base of the thalamus. In addition, aqueous humor could perhaps be absorbed by the ciliary body [11, 13]. After early postoperative
reduction, the average IOP continues to decline gradually over a period of 6 months before reaching a relatively constant level. It can be speculated that newly formed blood vessels and lymph vessels close to the surgical site, may contribute to the decrease of IOP level during follow-up [10].
In the literature, the success rate for trabeculectomy ranges between 57 and 96% [2, 14Ð26], for deep sclerectomy without collagen device between 57 and 74%, and for deep sclerectomy with collagen device between 58 and 90% [14, 27Ð29]. The sclerothalamotomy ab interno technique with a complete success rate of 90.6% after 24-month follow-up [30], 83% after 48 months and 79.2% after 72 months for open-angle glaucoma is comparable with other so far published surgery methods. The complete success rate for juvenile glaucoma after 48-month follow-up is 80%.
Advantages of the sclerothalamotomy ab interno method, compared with trabeculectomy and perforating and nonperforating deep sclerectomy seem to be the low rate of postoperative complications and a constant level of reduced IOP. Hypotension, a frequent Þnding in trabeculectomy, perforating deep sclerectomy, and nonperforating deep sclerectomy, is a relatively rare postoperative complication. The most frequent early complications in trabeculectomy are hyphema (24.6%), shallow anterior chamber (23.9%), hypotony (24.3%), wound leak (17.8%), and choroidal detachment (14.1%). The most frequent late complications are cataract (20.2%), visual loss (18.8%), iris incarceration (5.1%), and encapsulated bleb (3.4%). After sclerothalamotomy ab interno cataract development was seen in 17% with only 5.7% loss of one line of visual acuity after 72 months for open-angle glaucoma. Compared with other techniques sclerothalamotomy ab interno seems to be a relatively safe surgical technique [14, 17, 27, 28, 31Ð33].
Transient IOP elevation after sclerothalamotomy ab interno may occur in the Þrst 6 weeks and can be
